中國(guó)藥科大學(xué)藥學(xué)院研究生導(dǎo)師介紹：郝海平

• 2025考研復(fù)試伴學(xué)班
• 2025考研復(fù)試標(biāo)準(zhǔn)班
• 2026考研英語(yǔ)全程班
• 26考研全科上岸規(guī)劃營(yíng)「擇校▪規(guī)劃▪備考」
• 中國(guó)藥科大學(xué)2025考研專業(yè)課復(fù)習(xí)資料「真題▪筆記▪講義▪題庫(kù)」

郝海平，博士、中國(guó)藥科大學(xué)教授，博士生導(dǎo)師。2006年于中國(guó)藥科大學(xué)獲博士學(xué)位，2012-2013年美國(guó)國(guó)家癌癥研究所訪問(wèn)學(xué)者。現(xiàn)任中國(guó)藥科大學(xué)藥學(xué)院院長(zhǎng)、2011計(jì)劃建設(shè)辦公室主任、“天然藥物活性組分與藥效”國(guó)家重點(diǎn)實(shí)驗(yàn)室副主任。

為國(guó)家杰出青年科學(xué)基金獲得者、長(zhǎng)江學(xué)者特聘教授；首批中組部青年拔尖人才、江蘇省特聘教授；2008年全國(guó)百篇優(yōu)秀博士學(xué)位論文獲得者、首批江蘇省杰出青年科學(xué)基金獲得者、江蘇省“333”高層次人才培養(yǎng)工程中青年科技領(lǐng)軍人才（第二層次）、第十一屆江蘇省十大青年科技之星、教育部新世紀(jì)人才、江蘇省五四青年獎(jiǎng)?wù)芦@得者。

主要從事代謝調(diào)控與靶標(biāo)發(fā)現(xiàn)/確證研究、中藥及天然藥物體內(nèi)過(guò)程及作用機(jī)理研究。構(gòu)建了較完善、普適的體內(nèi)外天然藥物復(fù)雜成分定性、定量分析與體內(nèi)過(guò)程研究的方法學(xué)體系，提出并建立了符合天然藥物多成分多靶標(biāo)作用特點(diǎn)的藥代動(dòng)力學(xué)研究理論與模式，并在揭示天然活性成分群代謝處置規(guī)律的基礎(chǔ)上，提出了“反向藥代動(dòng)力學(xué)”、代謝處置導(dǎo)向的作用靶標(biāo)與機(jī)理研究的學(xué)術(shù)思想；在膽汁酸、色氨酸等內(nèi)源活性代謝調(diào)控研究中取得重要研究成果。近年來(lái)，主持承擔(dān)國(guó)家重大新藥創(chuàng)制專項(xiàng)、國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目、重大研究計(jì)劃等重大研究課題、國(guó)家杰出青年科學(xué)基金等各類項(xiàng)目17項(xiàng)。作為主要完成人之一，獲國(guó)家科技進(jìn)步二等獎(jiǎng)2項(xiàng)（排名第三、第四）、2012年教育部科學(xué)技術(shù)進(jìn)步一等獎(jiǎng)（排名第二）。發(fā)表SCI論文100余篇，其中以第一和通訊作者在NatCommun,Trends Pharmacol Sci,Anal Chem,Drug MetabDispos等相關(guān)領(lǐng)域一流期刊發(fā)表SCI論文60余篇。

兼任中國(guó)藥學(xué)會(huì)應(yīng)用藥理專業(yè)委員會(huì)副秘書長(zhǎng)、世界中醫(yī)藥聯(lián)合會(huì)中藥免疫專業(yè)委員會(huì)常務(wù)理事、世界中醫(yī)藥聯(lián)合會(huì)中藥分析委員理事、美國(guó)化學(xué)會(huì)（ACS）及國(guó)際藥代動(dòng)力學(xué)學(xué)會(huì)（ISSX）會(huì)員；Acta Pharmaceutica Sinica B編委，為Mol Pharmaceut,Toxicol Sci,Curr Drug Metab,Drug Metab Dispos等藥學(xué)相關(guān)領(lǐng)域一流SCI期刊的同行審稿專家。

主要研究方向

1、內(nèi)源活性分子代謝調(diào)控與藥物靶標(biāo)/確證研究：綜合應(yīng)用分子生物學(xué)、代謝組學(xué)與蛋白質(zhì)組學(xué)技術(shù)，圍繞腫瘤等代謝性疾病，探索藥物作用新靶標(biāo)，側(cè)重于研究?jī)?nèi)源活性物質(zhì)如膽汁酸、短鏈脂肪酸等代謝調(diào)控；在此基礎(chǔ)上，研究臨床具有確切療效的中藥/天然藥物的作用靶標(biāo)與作用機(jī)理，探索創(chuàng)新藥物研發(fā)及藥物治療新理論方法。主要資助課題：國(guó)家杰出青年科學(xué)基金項(xiàng)目、國(guó)家自然科學(xué)基金面上項(xiàng)目、國(guó)家自然科學(xué)基金重大研究計(jì)劃等。

2、中藥/天然藥物復(fù)雜成分代謝處置規(guī)律與機(jī)理研究：在創(chuàng)建復(fù)雜成分體內(nèi)外分析技術(shù)平臺(tái)的基礎(chǔ)上，揭示中藥/天然活性成分（群）在生物體內(nèi)外的代謝處置規(guī)律與機(jī)理，闡明主要類群成分如苷類、黃酮類、生物堿類等活性成分群的構(gòu)代關(guān)系；探索天然活性成分調(diào)控藥物代謝酶/轉(zhuǎn)運(yùn)體的作用規(guī)律與機(jī)理，從而為基于天然藥物/中藥的創(chuàng)新藥物研發(fā)和藥物相互作用研究提供科學(xué)基礎(chǔ)。主要資助課題：國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目、江蘇省杰出青年科學(xué)基金項(xiàng)目、國(guó)家重大新藥創(chuàng)制專項(xiàng)項(xiàng)目等。

歡迎立志于從事科學(xué)研究的學(xué)生報(bào)考！

聯(lián)系方式：025-83271179;Email:hhp_770505@hotmail.com

附：近年代表性SCI論文

1.Zhou X, Cao L, Jiang C, Xie Y, Chen X, Krausz KW, Qi Y, Sun L, Shah YM, Gonzalez FJ, Wang G*, Hao H*. PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun, 2014, 2014 Sep 3; 5:4573. doi: 10.1038/ncomms5573.

2.Hao H, Zheng X, Wang G*. Insights to drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol Sci, 2014, 35(4):168-177.

3.Zheng X, Kang A, Dai C, Liang Y, Xie T, Xie L, Peng Y, Wang G*, Hao H*.Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-tandem mass spectrometry. Anal Chem. 2012 Nov 20;84(22):10044-51.

4.Gong, P.; Cui, N.; Wu, L.; Liang, Y.; Hao, K.; Xu, X.; Tang, W.; Wang, G*.; Hao, H*. Chemicalome and metabolome matching approach to elucidating biological metabolic networks of complex mixtures. Anal Chem, 2012; Mar 20;84(6):2995-3002

5.Cheng X, Liu F, Yan T, Zhou X, Wu L, Liao K, Wang G*, Hao H*. Metabolic Profile,Enzyme Kinetics, and Reaction Phenotyping of β-Lapachone Metabolism in Human Liver and Intestine in Vitro. Mol Pharm. 2012 9 (12), pp 3476–3485.

6.Long F, Yang H, Xu Y, Hao H*, Li P*. A strategy for the identification of combinatorial bioactive compounds contributing to the holistic effect of herbal medicines. Sci Rep. 2015 Jul 22;5:12361. doi: 10.1038/srep12361.

7.Wang H, Yan T, Xie Y, Zhao M, Che Y, Zhang J, Liu H, Cao L, Cheng X, Xie Y, Li F, Qi Q, Wang G, Hao H. Mechanism-based inhibitory and peroxisome proliferator-activated receptor α-dependent modulating effects of silybin on principal hepatic drug-metabolizing enzymes. Drug Metab Dispos. 2015 Apr;43(4):444-54.

8.Zhang J, Cao L, Wang H, Cheng X, Wang L, Zhu L, Yan T, Xie Y, Wu Y, Zhao M, Ma S, Wu M, Wang G, Hao H*. Ginsenosides Regulate PXR/NF-κB Signaling and Attenuate Dextran Sulfate Sodium-Induced Colitis. Drug Metab Dispos. 2015 Aug;43(8):1181-9

9.Zheng X, Zhang X, Wang G, Hao H*.Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder. Drug Discov Today. 2015 May;20(5):562-8.

10.Zheng X, Zhang X, Kang A, Ran C, Wang G, Hao H. Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way? Neuropharmacology. 2015 Sep;96(Pt A):94-104.

11.Xie, Y.; Wang, G.; Wang, H.; Yao, X.; Jiang, S.; Kang, A.; Zhou, F.; Xie, T.; Hao, H*. Cytochrome P450 Dysregulations in Thioacetamide Induced Liver Cirrhosis in Rats and the Counteracting Effects of Hepatoprotective Agents. Drug Metab Dispos, 2012, Apr;40(4):796-802

12.Xie, T.; Liang, Y.; Hao, H*.; A, J.; Xie, L.; Gong, P.; Dai, C.; Liu, L.; Kang, A.; Zheng, X.; Wang, G*. Rapid identification of ophiopogonins and ophiopogonones in Ophiopogon japonicus extract with a practical technique of mass defect filtering based on high resolution mass spectrometry. J Chromatogr A, 2012, 1227, 234-44.

13.Wu L, Gong P, Wu Y, Liao K, Shen H, Qi Q, Liu H, Wang G*, Hao H*. An integral strategy toward the rapid identification of analogous nontarget compounds from complex mixtures. J Chromatogr A. 2013 Aug 16;1303:39-47.

14.Tang Z, Wu M, Li Y, Zheng X, Liu H, Cheng X, Xu L, Wang G*, Hao H*. Absolute quantification of NAD(P)H:quinone oxidoreductase 1 in human tumor cell lines and tissues by liquid chromatography-mass spectrometry/mass spectrometry using both isotopic and non-isotopic internal standards. Anal Chim Acta. 2013 Apr 15;772:59-67

15.Wu L, Wu Y, Shen H, Gong P, Cao L, Wang G*, Hao H*. Quantitative structure–ion intensity relationship strategy to the prediction of absolute levels without authentic standards. Anal Chim Acta. 2013 Sep 10;794:67-75.

16.Kang, A.; Hao, H*; Zheng, X.; Liang, Y.; Xie, Y.; Xie, T.; Dai, C.; Zhao, Q.; Wu, X.; Xie, L.; Wang, G*. Peripheral anti-inflammatory effects explain the ginsenosides paradox between poor brain distribution and anti-depression efficacy. J Neuroinflammation, 2011; 8:100.

17.Hao, H.; Zhang, L.; Jiang, S.; Sun, S.; Gong, P.; Xie, Y.; Zhou, X.; Wang, G*. Thioacetamide intoxication triggers transcriptional up-regulation but enzyme inactivation of UDP-glucuronosyltransferases. Drug Metab Dispos, 2011, 39 (10), 1815-22.

18.Hao H, Lai L, Zheng C, Wang Q, Yu G, Zhou X, Wu L, Gong P, Wang G.* Microsomal cytochrome P450 mediated metabolism of protopanaxatriol ginsenosides: metabolites profile, reaction phenotyping, and structure metabolism relationship, Drug Metab Dispos, 2010;38(10):1731-9.

19.Hao H, Cui N, Wang G*, Xiang B, Liang Y, Xu X, Zhang H, Yang J, Zheng C, Wu L, Gong P, Wang W. Global Detection and Identification of Non-target Components from Herbal Preparations by Liquid Chromatography Hybrid Ion-Trap Time-of-Flight Mass Spectrometry and a Novel Strategy. Anal Chem, 2008;80(21):8187-94.

20.Hao H, Wang G* and Sun J Enantioselective pharmacokinetics of ibuprofen and involved mechanisms.Drug Metab Rev.2005; 37(1):215-234.